B2M and androgen insensitivity syndrome: Additionally, AIS patients with plasma B2M levels over 2.31 mg/L are more susceptible to disease recurrence, which suggests B2M may act as a potential biomarker for predicting recurrence in these patients (Hu et al. 2022).